전체 프로그램

ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs
CGTLimited DatastaleNeotropixPhase 1

biological agent (Seneca Valley Virus, Seneca Valley Virus (biological agent))

Carcinoid; Neuroendocrine · Carcinoid

#Carcinoid#CGT#Phase1#Popular#cell-gene-therapy+5
Trials 93Status Active
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 1

T-cell Receptor-engineered T-cells (T-cell Receptor-engineered T-cells)

Prostate Carcinoma; Prostate Small Cell Neuroendocrine Carcinoma · Metastatic Malignant Solid Neoplasm

#MetastaticMalignantSolidNeoplasm#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 32Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous B7-H3 CAR T (Autologous B7-H3 CAR T)

Extensive-Stage Small Cell Lung Cancer; Extrapulmonary Neuroendocrine Carcinoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleBioXcel Therapeutics IncPhase 2

pembrolizumab (Keytruda, BXCL701 plus Pembrolizumab)

Prostate Cancer; Neuroendocrine Tumors · Prostate Cancer

#ProstateCancer#Antibody#Phase2#monoclonal-antibody#NeuroendocrineTumors+1
Trials 1Status Active
CGTLimited DatastaleChimeric TherapeuticsPhase 2

CHM-2101 CAR-T cells (CHM-2101 CAR-T cells)

Neuroendocrine Tumors; Colorectal Cancer · Neuroendocrine Tumors

#NeuroendocrineTumors#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting